Hu3F8 Antibody Dosing With Granulocyte-Macrophage CSF in Patients With Resistant Neuroblastoma

This phase 1 clinical trial examines the escalation and safety of humanized anti-G_D2 antibody doses in combination with granulocyte-macrophage colony-stimulating factor for treating patients with high-risk neuroblastoma.

https://ift.tt/2QKqO6S